Parker Institute, MD Anderson and Seres developing a microbiome/PD-1/L1 combo; CRISPR-Cas antimicrobial biotech Locus raises $17M
→ Just days ago, MD Anderson researcher Jennifer Wargo and colleagues published new research that showed how the gut microbiome played a big role in determining whether or not a checkpoint therapy could help save your life. This morning, MD Anderson and the scientific network aficionados at the Parker Institute have put a deal together to collaborate with leading micriobiome biotech Seres on a pill. Seres’ $MCRB bacteria pill is the preclinical SER-401. And the biotech landed a deal for MD Anderson’s IP. The Parker Institute will sponsor a clinical trial to see if it works.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
